Age Legislation Cuts Off-Road-Vehicle-Related Injury Rate

Share this content:
Age Legislation Cuts Off-Road-Vehicle-Related Injury Rate
Age Legislation Cuts Off-Road-Vehicle-Related Injury Rate

MONDAY, Sept. 11, 2017 (HealthDay News) -- The population-based rate of off-road-vehicle (ORV)-related injuries was reduced following a 2010 Massachusetts law restricting their use by children aged younger than 14 years and regulating their use by children up to age 18 years, according to a study published online Sept. 11 in Pediatrics.

Michael R. Flaherty, D.O., from Massachusetts General Hospital in Boston, and colleagues conducted a retrospective analysis of Massachusetts emergency department and inpatient discharges between 2002 and 2013 by using external causes of injury codes specific for ORV-related injuries. The authors compared the yearly population-based rates before and after implementation of the law (2002 to 2010 versus 2011 to 2013).

The researchers found that across the 12-year study period, there were 3,638 emergency department discharges and 481 inpatient discharges for ORV-related injuries in children. The rate of emergency department discharges decreased by 33, 50, and 39 percent, respectively, in 0- to 9-year-olds, 10- to 13-year-olds, and 14- to 17-year-olds after implementation of the law (P < 0.0001). No significant decreases in emergency department discharges were seen for 25- to 34-year-olds. After implementation, there was a reduction of 41 percent in inpatient hospital discharges for 0- to 17-year-olds (P < 0.001).

"As compared with adults (ages 25 to 34 years), the population-based ORV-related injury rate of residents <18 years old significantly declined after the passage of legislation that imposed age restrictions and other safeguards for youth riders," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »